Pneumagen’s lead product, Neumifil™, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV). Neumifil™ has the potential to revolutionise the treatment of flu by providing clinicians with the opportunity to offer their patients total protection against all influenza viral strains, thus overcoming the limitations of current vaccines and other therapeutic approaches.
Neumifil – A sialidase-derived CBM40 from Streptococcus pneumoniae engineered to create multivalent high-affinity hexamers
When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of IFV infection with no observed toxicity. CBM40s Neumifil™ has also been shown to be effective in other viruses, such as Respiratory Syncytial Virus (RSV) and parainfluenza and is also under development for these indications.
Clinical Development Plan
Pneumagen is completing preclinical activities in IFV. This would be followed by a Phase I clinical trial and challenge study with the goal of providing early clinical proof of concept.
Neumifil™ will be administered intranasally and will initially target high-risk groups such as the elderly, immuno-compromised and those with underlying lung disease such as asthma and COPD.